We are live on ! Find out more
ACRS icon

Aclaris Therapeutics
ACRS

126 hedge funds and large institutions have $1.02B invested in Aclaris Therapeutics in 2021 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 51 increasing their positions, 36 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

188% more call options, than puts

Call options by funds: $2.33M | Put options by funds: $807K

42% more repeat investments, than reductions

Existing positions increased: 51 | Existing positions reduced: 36

4% more capital invested

Capital invested by funds: $980M → $1.02B (+$42.5M)

0% more funds holding in top 10

Funds holding in top 10: 8 → 8 (0)

5% less first-time investments, than exits

New positions opened: 21 | Existing positions closed: 22

2% less funds holding

Funds holding: 128 → 126 (-2)

1.93% less ownership

Funds ownership: 94.68% → 92.76% (-1.9%)

Holders
126
Holders Change
-2
Holders Change %
-1.56%
% of All Funds
2.21%
Holding in Top 10
8
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.14%
New
21
Increased
51
Reduced
36
Closed
22
Calls
$2.33M
Puts
$807K
Net Calls
+$1.52M
Net Calls Change
+$1.08M

Top Buyers

Rank Fund Capital Flow
1
Wellington Management Group
Wellington Management Group
Massachusetts
+$11.6M
2
WP
Woodline Partners
California
+$9.53M
3
Holocene Advisors
Holocene Advisors
New York
+$8.93M
4
BlackRock
BlackRock
New York
+$8.81M
5
CC
Commodore Capital
New York
+$8.36M

Top Sellers

Rank Fund Capital Flow
1
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$14.8M
2
LGM
Logos Global Management
California
-$11.9M
3
CAM
Cormorant Asset Management
Massachusetts
-$8.02M
4
VC
Vivo Capital
California
-$6.95M
5
Renaissance Technologies
Renaissance Technologies
New York
-$6.59M
Name Holding Trade Value Shares
Change 		Change in
Stake
SSA
26
Schonfeld Strategic Advisors
New York
$9.23M +$4.14M +258,531 +102%
Northern Trust
27
Northern Trust
Illinois
$9.03M +$725K +45,197 +10%
GPP
28
Great Point Partners
Connecticut
$9M +$8.02M +500,000 New
LCM
29
Laurion Capital Management
New York
$8.87M -$660K -41,162 -8%
Assenagon Asset Management
30
Assenagon Asset Management
Luxembourg
$8.52M -$1.66M -103,507 -18%
Goldman Sachs
31
Goldman Sachs
New York
$7.94M +$1.86M +115,819 +36%
Invesco
32
Invesco
Georgia
$7.9M +$6.72M +418,886 +2,103%
FM
33
Frazier Management
Washington
$7.35M +$603K +37,596 +10%
Point72 Asset Management
34
Point72 Asset Management
Connecticut
$7.04M -$1.4M -87,300 -18%
AAA
35
Affinity Asset Advisors
New York
$6.3M +$1.2M +75,000 +27%
Deutsche Bank
36
Deutsche Bank
Germany
$5.8M -$189K -11,795 -4%
Millennium Management
37
Millennium Management
New York
$5.78M +$1.94M +120,827 +60%
GTC
38
Ghost Tree Capital
New York
$4.95M +$401K +25,000 +10%
N
39
Nuveen
North Carolina
$4.94M +$1.42M +88,303 +48%
ACM
40
Asymmetry Capital Management
California
$4.35M -$1.19M -74,133 -23%
IHAM
41
Integral Health Asset Management
New York
$3.33M +$160K +10,000 +6%
Bank of New York Mellon
42
Bank of New York Mellon
New York
$3.28M +$754K +47,003 +35%
JGC
43
J. Goldman & Co
New York
$3.2M +$2.22M +138,651 +355%
SCM
44
Silverarc Capital Management
Massachusetts
$3.12M -$247K -15,392 -8%
Balyasny Asset Management
45
Balyasny Asset Management
Illinois
$2.91M +$119K +7,423 +5%
DGM
46
Darwin Global Management
Jersey
$2.87M -$1.45M -90,607 -36%
ACP
47
Acuta Capital Partners
California
$2.54M -$548K -34,161 -20%
JC
48
Jetstream Capital
Tennessee
$2.52M +$2.24M +140,000 New
Charles Schwab
49
Charles Schwab
California
$2.29M +$306K +19,078 +18%
Wells Fargo
50
Wells Fargo
California
$2.17M +$1.91M +119,438 +10,750%
1
2
3 4 5

ACRS Hedge Fund Activity: Q3 2021 in Review

126 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Aclaris Therapeutics (ACRS) for Q3 2021, worth a combined $1.02B — up 4.3% from $980M a quarter earlier.

Sellers outnumbered buyers: 22 funds closed out of ACRS and 21 opened new positions — a net loss of 1 holder — while 36 trimmed existing stakes and 51 added.

The largest buyer was Wellington Management Group, adding an estimated $11.6M. The largest seller was Adage Capital Partners, cutting an estimated $14.8M.

  • 126 institutional investors held Aclaris Therapeutics (ACRS) as of Q3 2021, down from 128 in Q2 2021.
  • Funds reported $1.02B of Aclaris Therapeutics stock for Q3 2021, up 4.3% quarter-over-quarter.
  • 21 funds opened new Aclaris Therapeutics positions in Q3 2021 and 22 closed out, a net change of -1 holder.
  • The largest Aclaris Therapeutics buyer in Q3 2021 was Wellington Management Group, an estimated $11.6M added.
  • The largest Aclaris Therapeutics seller in Q3 2021 was Adage Capital Partners, an estimated $14.8M sold.

Based on aggregated 13F filings for Q3 2021.